SAN FRANCISCO, April 20, 2017 — McKesson Corporation learned today that the Arkansas Supreme Court has issued a stay of the preliminary injunction order granted by the Circuit Court of Pulaski County Arkansas. McKesson issues the following statement in response to the court ruling:
We believe we have done all we can do at this time to recover our product. We are disappointed that the Arkansas Supreme Court has held our favorable injunction ruling in abeyance and delayed further scheduling in our case.
***
SAN FRANCISCO, April 19, 2017 — Today, McKesson Corporation was granted a temporary restraining order by the Circuit Court of Pulaski County Arkansas that prohibits the Arkansas Department of Correction from using vecuronium bromide obtained by McKesson. McKesson issues the following statement in response to the court ruling:
We are pleased that the court has ruled in our favor and we look forward to the return of our product.
***
SAN FRANCISCO, April 18, 2017 — McKesson Corporation issues the following statement regarding the company’s filing a new legal action in the Circuit Court of Pulaski County Arkansas:
McKesson has filed a new action in Pulaski County Circuit Court for review by the new judge who has now been assigned to these matters, and again seeks a restraining order to prevent the use of our product for something other than a legitimate medical purpose. McKesson is committed to ensuring that its property is only used in a manner consistent with our supplier agreement.
***
SAN FRANCISCO, April 15, 2017 — McKesson Corporation issues the following statement in response to McKesson’s withdrawal of its request for a temporary restraining order, originally granted on April 14, 2017:
In light of this morning’s issuance of a preliminary injunction prohibiting the State of Arkansas from proceeding with its planned executions, there is no longer imminent danger of McKesson’s property being used in a manner that is inconsistent with our supplier agreement. As a result, McKesson has withdrawn its request for a temporary restraining order, preserving its ability to refile should the Arkansas Department of Correction be given the right to proceed at a future date.
We will continue our efforts to facilitate the return of our product and ensure that it is used in line with our supplier agreement.
***
SAN FRANCISCO, April 14, 2017 — Today, McKesson Corporation was granted a temporary restraining order by the Circuit Court of Pulaski County Arkansas that prohibits the Arkansas Department of Correction from using vecuronium bromide obtained by McKesson for lethal injection purposes until otherwise notified by the Court.
McKesson issues the following statement in response to the court ruling:
We are pleased that the court has ruled in our favor and we look forward to the return of our product.
***
SAN FRANCISCO, April 13, 2017 — McKesson Corporation issues the following statement in response to the Arkansas Department of Correction’s planned executions:
The Arkansas Department of Correction intentionally sought to circumvent McKesson’s policies to procure Pfizer’s vecuronium bromide under the auspices that it would be used for medical purposes in ADC’s health facility. Upon learning that ADC was potentially holding the product for lethal injection purposes, McKesson immediately requested and was assured by ADC that the product would be returned. McKesson issued a full refund to ADC, and made several additional requests for the product, but the product was never returned.
As of April 13, 2017, ADC continues to hold McKesson’s product despite the company’s repeated attempts to compel ADC to either return the product or assure us in writing that the products will not be used for lethal injection purposes. McKesson is considering all possible means by which to secure the return of the product, up to and including legal action.
About McKesson Corporation
McKesson Corporation, currently ranked 5th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, our 70,000 employees across more than 16 countries work every day to innovate and deliver opportunities that make our customers and partners more successful — all for the better health of patients. McKesson has been named the “Most Admired Company” in the healthcare wholesaler category by FORTUNE, a “Best Place to Work” by the Human Rights Campaign Foundation, a top military-friendly company by Military Friendly®, and a “Best Employer for Healthy Lifestyles” by The National Business Group on Health. For more information, visit www.McKesson.com.